Cytomegalovirus inhibitor compounds

A compound of Formula (I):

• wherein
• m is 1, 2 or 3;
• n is 1, 2 or 3;
• R1 is halo, —CN, (C1-6)alkyl, OH, —O—(C1-6)alkyl, (C1-6)haloalkyl or nitro;
• R2 is H or (C1-6)alkyl optionally substituted with halo, —CN, (C1-6)alkyl, (C1-6)haloalkyl, —(C3-7)cycloalkyl , —O—(C1-6)alkyl, OH ,—NH2, —NH(C1-6)alkyl or —N((C1-6)alkyl)2;
• R3 is H, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, heterocyclyl, heteroaryl, —(C1-6)alkyl-(C3-7)cycloalkyl, —(C1-6)alkyl-aryl, —(C1-6)alkyl-heterocyclyl or —(C1-6)alkyl-heteroaryl, wherein each said alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, either alone or in combination with another radical, is optionally mono-, di-, or tri-substituted with R32;
• or R2 and R3, together with the N to which they are attached, are linked to form a heterocyclyl or heteroaryl;
• wherein each said heterocyclyl and heteroaryl are optionally mono-, di-, or tri-substituted with R32;
• R32 is each independently selected from the group consisting of R33, halo, oxo, —CN, OH, SH, —COOH, —O—(C1-6)alkyl, —S—(C1-6)alkyl, (C3-7)cycloalkyl, (C1-6)haloalkyl, —C(═O)—(C1-6)alkyl, —C(═O)—O—(C1-6)alkyl, —SO2NH2, —SO2—NH(C1-6)alkyl, —SO2—N((C1-6)alkyl)2, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, —C(═O)—NH2, —C(═O)—NH(C1-6)alkyl, —C(═O)—N((C1-6)alkyl)2, —C(═O)—NH—SO2(C1-6)alkyl, —SO2—NH—C(═O)—(C1-6)alkyl, —NH2, —NH(C1-6)alkyl, —N((C1-6)alkyl)2, —NH(C3-7)cycloalkyl, —N((C1-6)alkyl)(C3-7)cycloalkyl, —NH—C(═O)(C1-6)alkyl, —NH—C(═O)—O(C1-6)alkyl, heterocyclyl (optionally substituted with (C1-6)alkyl) and heteroaryl (optionally substituted with (C1-6)alkyl);
• R33 is (C1-6)alkyl optionally mono-or di-substituted with OH, —O—(C1-6)alkyl, —NH2, —NH(C1-6)alkyl or —N((C1-6)alkyl)2;
• R4, R5 and R6 are each independently selected from the group consisting of halo, —CN, nitro, R42, —C(═O)—R42, —C(═O)OR42, —OR42, —SR42, —SOR42, —SO2R42, —N(R43)R42, —(C1-6)alkyl—N(R43)R42, —C(═O)—N(R43)R42, —N(R43)—C(═O)R42, —N(R43)—C(═O)—OR42, —O—C(═O)—N(R43)R42, —C(═O)—N(H)—SO2R42, —SO2—N(H)—C(═O)R42, —N(R43)—SO2R42 and —SO2—N(R43)R42;
• R42 is each independently selected from the group consisting of H, (C1-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, —(C1-6)alkyl-(C3-7)cycloalkyl, —(C1-6)alkyl-aryl, —(C1-6)alkyl-heterocyclyl, —(C1-6)alkyl-heteroaryl, (C3-7)cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein each said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, either alone or in combination with another radical, is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of:
• oxo, halo, —CN, OH, —COOH, —O—(C1-6)alkyl, —S—(C1-6)alkyl, (C3-7)cycloalkyl, —O—(C3-7)cycloalkyl, (C1-6)haloalkyl, —C(═O)—O—(C1-6)alkyl, —SO2NH2, —SO2—NH(C1-6)alkyl, —SO2—N((C1-6)alkyl)2, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, —C(═O)—NH2, —C(═O)—NH(C1-6)alkyl, —C(═O)—N((C1-6)alkyl)2, —NH2, —NH(C1-6)alkyl, —N((C1-6)alkyl)2, —NH—C(═O)(C1-6)alkyl, —NH—C(═O)—O—(C1-6)alkyl, —C(═O)—N(H)—SO2(C1-6)alkyl, —SO2—N(H)—C(═O)(C1-6)alkyl, and (C1-6)alkyl optionally mono-or di-substituted with OH, —O—(C1-6)alkyl, —S—(C1-6)alkyl, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, —NH2, —NH(C1-6)alkyl, —N((C1-6)alkyl)2, —C(═O)-heterocyclyl, —C(═O)-heteroaryl, aryl, heterocyclyl or heteroaryl;
• R43 is H, (C1-6)haloalkyl or (C1-6)alkyl optionally mono-or di-substituted with OH, —O—(C1-6)alkyl, or —O—(C3-7)cycloalkyl;
• or a salt thereof.